This study is testing two medicines, pepinemab and pembrolizumab, to see if they are safe and helpful for people with a type of cancer called recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC). Squamous cell carcinoma is a common type of skin cancer that can also occur in the head and neck area. This study will help find the right dose of the medicines for the future. It has two parts: first, a safety run-in phase to check safety, and then a dose expansion phase to see how well the medicines work. During the study, patients will have regular check-ups to see how they are responding to the treatment.
- Study Duration: This study may last up to 2 years.
- Visits: Participants will have evaluations at baseline, week 9, every 6 weeks for the first year, and every 9 weeks thereafter.
- Eligibility: Participants must be 18 or older and have specific types of head and neck cancer.
How understandable was the trial content above?
Hard to understand
Easy to understand